Getting to Lower Prescription Drug Prices in the United States: How Do Other Countries Do It?

Agenda

2:00 – 2:05 p.m.       Introduction:

• Robin Osborn, Vice President and Director, International
  Health Policy and Practice Innovations, the Commonwealth Fund
• Shawn Bishop, Vice President, Controlling Health Care Costs and Advancing Medicare, the Commonwealth Fund

2:05 – 2:30 p.m.                      

• Steve Morgan, Professor, Health Services and Policy, The University of British Columbia
• Ruth Lopert, Adjunct Professor, George Washington School of Public Health, former Chief Medical Officer, Australia’s Therapeutic Goods Administration
• James Robinson, Leonard D. Schaeffer Endowed Chair in Health Economics, University of California Berkeley

2:30 p.m.       Q and A

Additional Resources

• James Robinson.  “Pharmaceutical Reference Pricing: Does It Have a Future in the U.S.?”  The Commonwealth Fund, September 2018. https://www.commonwealthfund.org/publications/issue-briefs/2018/sep/pharmaceutical-reference-pricing-future
• Steven Morgan, Augustine Lee. "Cost-Related Non-Adherence to Prescribed Medicines Among Older Adults in Eleven Developed Countries: A Cross-Sectional Analysis of a Survey in 11 Developed Countries," BMJ Open, January 2017. https://bmjopen.bmj.com/content/7/1/e014287
• Steven Morgan, Sabine Vogler, Anita Wagner. "Payers’ Experiences with Confidential Pharmaceutical Price Discounts: A Survey of Public and Statutory Health Systems in North America, Europe, and Australasia," Health Policy, March 2017. https://www.sciencedirect.com/science/article/pii/S0168851017300301?via%3Dihub
• Steven Morgan, Christine Leopold, Anita Wagner. "Drivers of Expenditure on Primary Care Prescription Drugs in 10 High-Income Countries with Universal Health Coverage," Canadian Medical Association Journal, June 2017. http://www.cmaj.ca/content/189/23/E794
• Steven Morgan, Chester B. Good, Christine Leopold, Anna Kaltenboeck, Peter B. Bach, Anita Wagner. "An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries," Health Policy, July 2018. https://www.sciencedirect.com/science/article/pii/S016885101830246X?via%3Dihub
• Salas-Vega, S, Mossialos, E. “Cancer Drugs Provide Positive Value In Nine Countries, But The United States Lags In Health Gains Per Dollar Spent,” Health Affairs, May 2016. https://www.healthaffairs.org/doi/10.1377/hlthaff.2015.1453
• D. O. Sarnak, D. Squires, G. Kuzmak, and S. Bishop. “Paying for Prescription Drugs Around the World: Why Is the U.S. an Outlier?” The Commonwealth Fund, October 2017. https://www.commonwealthfund.org/publications/podcast/2017/oct/why-are-us-prescription-drug-prices-so-high
• Summaries of National Drug Coverage and Pharmaceutical Pricing Policies in 10 Countries: Australia, Canada, France, Germany, the Netherlands, New Zealand, Norway, Sweden, Switzerland and the U.K., Working Papers for the 2016 Meeting of the Vancouver Group. https://www.commonwealthfund.org/sites/default/files/2018-09/Steven%20Morgan%2C%20PhD_Ten%20Country%20Pharma%20Policy%20Summaries_2016%20Vancouver%20Group%20Meeting.pdf 

• Bruen B, Docteur E, Lopert R, Cohen J, DiMasi J, et al. The impact of reimbursement policies and practices on healthcare technology innovation. (Washington DC; DHHS Office of the Assistant Secretary for Planning & Evaluation, 2016).